Sinew Pharma (TPEX:6634) - Share price, News & Analysis

6634 fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

6634 Stock Overview

Sinew Pharma Inc., a biopharmaceutical company, focuses on the development and sale of drugs for the treatment of hepatotoxicity-free acetaminophen and fatty liver diseases.

Risk Analysis

Earnings have declined by 2.8% per year over past 5 years

Makes less than USD$1m in revenue (NT$6M)

Shareholders have been diluted in the past year

Sinew Pharma Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Sinew Pharma
Historical stock prices
Current Share Price	NT$79.80
52 Week High	NT$99.00
52 Week Low	NT$62.10
Beta	1.52
1 Month Change	-5.00%
3 Month Change	-0.50%
1 Year Change	-0.75%
3 Year Change	179.90%
5 Year Change	n/a
Change since IPO	60.24%

Recent News & Updates

Mar 11

Companies Like Sinew Pharma (GTSM:6634) Can Afford To Invest In Growth

There's no doubt that money can be made by owning shares of unprofitable businesses. Indeed, Sinew Pharma ( GTSM:6634...

Nov 25

Sinew Pharma (GTSM:6634) Is In A Strong Position To Grow Its Business

Just because a business does not make any money, does not mean that the stock will go down. Indeed, Sinew Pharma...

Shareholder Returns

	6634	TW Pharmaceuticals	TW Market
7D	-2.9%	-4.6%	-3.4%
1Y	-0.7%	3.0%	0.7%

Return vs Industry: 6634 underperformed the TW Pharmaceuticals industry which returned 3% over the past year.

Return vs Market: 6634 underperformed the TW Market which returned 0.7% over the past year.

Price Volatility

Is 6634's price volatile compared to industry and market?
6634 volatility
6634 Average Weekly Movement	5.6%
Pharmaceuticals Industry Average Movement	5.4%
Market Average Movement	4.6%
10% most volatile stocks in TW Market	8.3%
10% least volatile stocks in TW Market	2.1%

Stable Share Price: 6634 is not significantly more volatile than the rest of TW stocks over the past 3 months, typically moving +/- 6% a week.

Volatility Over Time: 6634's weekly volatility (6%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
2013	33	Kaimin Chu	https://www.sinewpharma.com

Sinew Pharma Inc., a biopharmaceutical company, focuses on the development and sale of drugs for the treatment of hepatotoxicity-free acetaminophen and fatty liver diseases. The company’s products include SNP-610 drug, which is in Phase II clinical trial for treating patients with non-alcoholic steatohepatitis in Taiwan; and SNP-630, a pre-clinical drug for treating patients with non-alcoholic steatohepatitis. It is also developing SNP-810 for use in analgesic and antipyretic indications; and SNP-830 and SNP-840, which are used as hepatotoxicity-free analgesic medicines in the United States.

Sinew Pharma Fundamentals Summary

How do Sinew Pharma's earnings and revenue compare to its market cap?
6634 fundamental statistics
Market Cap	NT$5.51b
Earnings (TTM)	-NT$91.57m
Revenue (TTM)	NT$6.23m

884.7x

P/S Ratio

-60.2x

P/E Ratio

Is 6634 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report
6634 income statement (TTM)
Revenue	NT$6.23m
Cost of Revenue	NT$1.14m
Gross Profit	NT$5.09m
Other Expenses	NT$96.67m
Earnings	-NT$91.57m

Last Reported Earnings

Dec 31, 2021

Next Earnings Date

n/a

Earnings per share (EPS)	-1.33
Gross Margin	81.75%
Net Profit Margin	-1,470.14%
Debt/Equity Ratio	0%

How did 6634 perform over the long term?

See historical performance and comparison

Valuation

Is Sinew Pharma undervalued compared to its fair value and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PEG Ratio
PB vs Industry

3.51x

Price to Book (PB) ratio

Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate 6634's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 6634's fair value for valuation analysis.

Price To Earnings Ratio

PE vs Industry: 6634 is unprofitable, so we can't compare its PE Ratio to the TW Pharmaceuticals industry average.

PE vs Market: 6634 is unprofitable, so we can't compare its PE Ratio to the TW market.

Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 6634's PEG Ratio to determine if it is good value.

Price to Book Ratio

PB vs Industry: 6634 is overvalued based on its PB Ratio (3.5x) compared to the TW Pharmaceuticals industry average (2x).

Future Growth

How is Sinew Pharma forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE

50.2%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Sinew Pharma has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Past Performance

How has Sinew Pharma performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE

-2.8%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: 6634 is currently unprofitable.

Growing Profit Margin: 6634 is currently unprofitable.

Past Earnings Growth Analysis

Earnings Trend: 6634 is unprofitable, and losses have increased over the past 5 years at a rate of 2.8% per year.

Accelerating Growth: Unable to compare 6634's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 6634 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-7.6%).

Return on Equity

High ROE: 6634 has a negative Return on Equity (-5.84%), as it is currently unprofitable.

Financial Health

How is Sinew Pharma's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Stable Cash Runway
Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: 6634's short term assets (NT$1.5B) exceed its short term liabilities (NT$15.1M).

Long Term Liabilities: 6634's short term assets (NT$1.5B) exceed its long term liabilities (NT$850.0K).

Debt to Equity History and Analysis

Debt Level: 6634 is debt free.

Reducing Debt: 6634 has not had any debt for past 5 years.

Balance Sheet

Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: 6634 has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: 6634 has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 4.1% each year

Dividend

What is Sinew Pharma current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate 6634's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate 6634's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 6634's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 6634's dividend payments have been increasing.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as 6634 has not reported any payouts.

Next Steps

Explore strong dividend paying companies in the Pharmaceuticals & Biotech industry.

Management

How experienced are the management team and are they aligned to shareholders interests?

CEO

Kaimin Chu

no data

Tenure

Dr. Kaimin Chu MD, PhD, serves as the Chairman & Chief Executive Officer at Sinew Pharma Inc. Dr. Chu served as Director of the Clinical Research Center and Director of Cardiology at the Tri-Service Genera...

Ownership

Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 32.1%.

Data	Last Updated (UTC time)
Company Analysis	2022/05/15 00:00
End of Day Share Price	2022/05/13 00:00
Earnings	2021/12/31
Annual Earnings	2021/12/31